Orug Diversion Toolking

Prescription Drug Trafficking—Recognizing Suspicious Prescriptions







Content Summary

This booklet educates pharmacy personnel about characteristics of prescriptions that indicate the prescription may be fraudulent. The information presented helps pharmacists recognize what circumstances should trigger a particularly thorough and comprehensive review of a prescription before filling. The booklet describes how to identify acceptable Centers for Medicare & Medicaid Services (CMS) tamper-resistant characteristics, while recognizing circumstances that require secondary prescription verification before filling. This booklet also enables pharmacists to recognize distinctive traits of new prescriptions that may suggest a questionable origin and which secondary prescription verification steps to take in these instances. Guidance is provided to assist pharmacists who suspect or identify prescription tampering or prescriptions of questionable origin.



Recognizing Tampering

National and local headlines are littered with tales of prescription drug trafficking run amuck.[1] The allure of quick and easy money draws in small-time crooks, syndicated crime rings, and even health care professionals who appear to be reputable members of the local community. It is imperative that pharmacists exercise due diligence to determine whether a prescription presented to be filled is, in fact, a legitimate prescription. Pharmacists, pharmacy interns, and pharmacy technicians should know how to inspect new prescriptions for evidence of tampering and should be able to recognize traits of new prescriptions that may suggest a questionable origin.

Tamper-Prevention Categories

Performing a thorough inspection of the prescription hard copy is essential to ensure controlled substance integrity. This step may help identify a prescription that has been photocopied or altered. Since October 1, 2008, Federal law has required that printed prescriptions issued to Medicaid patients comply with three characteristics to be considered tamper-resistant.[2] Prescriptions must have:

- 1. One or more industry-recognized features designed to prevent unauthorized copying of a completed or blank prescription form.
- 2. One or more industry-recognized features designed to prevent the erasure or modification of information written on the prescription pad by the prescriber.
- 3. One or more industry-recognized features designed to prevent the use of counterfeit prescription forms.

The requirement for industry-recognized security features does not apply to verbal, faxed, or electronic prescriptions; cases where a managed care organization pays for the prescription; or most institutional or clinical residential settings.[3] Become familiar with security features so staff can take appropriate measures to validate any prescription that appears to have been copied, altered, or forged. Table 1. Tamper-Resistant Technology and Secondary Verification lists the tamper-resistant technology suggested by the National Council for Prescription Drug Programs that prescribers may select in light of the Federal requirement and identifies circumstances that may require secondary prescription verification before filling.[4]

Table 1. Tamper-Resistant Technology and Secondary Verification

Tamper-Resistant Technology	Description	When Secondary Verification Is Required	Tamper-Resistant Category
Coin-rub	Rub a coin over the back of the prescription blank to view hidden security wording	If the security wording is not visible when rubbed	1; 3
Invisible fluorescent fibers	Fibers within the prescription blank papers that fluoresce under black light	If the fluorescent fibers do not appear under a black light	1;
Microprinting	Very small font (0.010), visible under magnification	If the microprinting line appears as a solid line or is illegible under magnification	1
Number of written prescriptions indicator	Prescription blank contains the phrase, "Rx is void if more than Rxs" appear	If the blank does not contain a number	2
Quantity check-off boxes	Quantity ranges, typically in increments of 25, with a check box next to the range	If no box is checked	2
Quantity/refill border and fill	The quantity prescribed and number of refills prescribed are preceded and followed by a distinctive character, such as an asterisk. May also include the numerical and alpha quantity characters.	If the border is not present or appears altered	2
Refill indicator	Mandatory inclusion of the number of refills on the prescription	If the number of refills is not indicated	2
Security features/warning band/warning list	A band of wording or list on the face of the prescription or back of the prescription that describes all security features present on the prescription blank	If one or more of the listed security features are not visible	1;
Special security paper/tamper-resistant background ink/nonwhite background color	Shows attempts to change written information through abrasion or chemicals	If a portion of the background appears lighter, darker, or altered. If the paper appears orange, green, or otherwise discolored.	1; 2
Thermochromatic ink/thermochromatic Rx symbol/sensing imprint	When designated text or symbol is rubbed or heated, a color change is observed. Imprint may disappear when touched.	If no color change is seen when rubbed or heated	1;
Toner bond or adhesion coating/color lock paper	The paper is designed to fuse with toner inks to prevent removal of printed text	If the paper appears torn or altered	2
Void pantograph/reverse Rx symbol	A word, such as void, illegal, or copy, is very light or not visible at all on the original paper prescription but is apparent if the paper is photocopied. An Rx symbol may appear white when photocopied.	If the words void, illegal, or copy appear across the face of the prescription or if a white Rx symbol is present. If the prescription is received as a facsimile, document this fact on the face of the prescription.	1
Watermark on reverse side of blank	Tip the page toward a light to see the watermark	If the watermark is not visible	1;

Noncompliant Prescriptions

Features that may be added by a prescriber to a noncompliant prescription blank, such as writing out drug quantities or using particular types of ink, do not satisfy the provisions of the Social Security Act's tamper-resistance amendment because the statute requires that the prescription be "executed on a tamper-resistant pad."[5] In addition, use of a pen does not satisfy the requirement of a feature that prevents erasure or alteration.[6] States may require additional tamper-resistant provisions that meet or exceed the three required categories. For example, the State of New York requires a serial number on the face of the prescription that must be included as part of the claims adjudication process before the prescription is validated.[7]

The National Council for Prescription Drug Programs strongly suggests prescribers include a listing of security features so pharmacists can identify the selected tamper-resistant features.[8] If the security feature listing is not included, use professional discretion when considering the tamper-resistant features that are present. If a prescription lacks a feature in any of the three required tamper-resistant categories, it is the duty of the pharmacist to call the prescriber and verify the prescription. Documentation by the pharmacy of a verbal prescriber confirmation on a noncompliant prescription satisfies the tamper-resistant requirements of the Federal law.[9]

Questionable Origin and Pill Mills

Pharmacists also have a duty to carefully examine prescriptions that appear questionable in origin. The starting point for a questionable prescription is often a fraudulent pain clinic, or pill mill, where prescribers write prescriptions for controlled substances in exchange for cash, without any intent to actually establish a provider–patient relationship. A pill mill provider prescribes and dispenses controlled substances outside of the usual scope of medical practice or violates the laws of the State as they pertain to controlled substances.[10] Florida recently stood at the epicenter of the pill mill crisis. Florida Attorney General Pam Bondi said that when she took office in 2011, of the nation's 100 highest-volume oxycodone prescribers, Florida physicians occupied 98 of the 100 spots. In 2013, Bondi announced that due to her efforts to shut down pill mills, there were no Florida physicians on the top prescriber list.[11]

In June 2013, Walgreens agreed to pay the largest civil penalty in Drug Enforcement Administration (DEA) history after the DEA found Walgreens pharmacists carelessly filled inordinately large numbers of oxycodone and other controlled substance prescriptions.[12] Walgreens acknowledged that its Florida distribution center failed to notify the DEA of unusually large, suspicious drug orders and acknowledged that some of its Florida pharmacists failed to fulfill their corresponding duty under Federal regulations to ensure proper prescribing and dispensing of controlled substances.[13]

Corresponding Responsibility

Pharmacists have a corresponding responsibility to physicians to ensure that prescriptions are written for a legitimate medical purpose.[14] If a provider is engaged in behavior that involves prescribing controlled substances outside of the realm of medical practice standards, a responsibility to recognize this behavior rests on the shoulders of the pharmacists accepting the prescription. If pharmacists are found not to have acted on their corresponding responsibility, they can be held liable and the right to dispense controlled substances can be revoked by the DEA.[15, 16] If a pharmacist fills prescriptions that were not issued for a legitimate medical purpose, he or she may also be subject to criminal prosecution.[17] The DEA contends that pharmacists could save lives by questioning, exercising professional judgment, and refusing to fill prescriptions that originate at "rogue" pain clinics.[18]



When and How to Verify

Pharmacists should check pharmacy records to determine if other providers have prescribed narcotics or other mediations with abuse potential. Forty-nine States have enacted legislation to create Prescription Monitoring Programs (PMPs), and 47 States have operational PMP programs.[19] If available, pharmacists should consult PMP data to view comprehensive information on prescribed and dispensed controlled substances that appear on Schedules II-V of the Controlled Substances Act. Question the origin of a prescription if aspects of the patient, provider, or prescription appear outside of the norm, but balance this responsibility with providing for the needs of lawful patients. If a questionable origin is suspected, attempt to verify the prescription. If the patient is not known to the pharmacist, ask the patient for identification and include that identification number on the prescription. Pharmacists may ask the patient what condition the medication is being used to treat. Contact the prescriber to confirm the prescription was issued by the prescriber and request that the prescriber provide the patient's diagnosis. If circumstances suggest that prescriber identity theft may have occurred, do not hesitate to ask to speak to the prescriber directly. Document all gathered information on the prescription blank.

Circumstances That May Require Secondary Verification

Patient, provider, or controlled substance prescription attributes or circumstances that may warrant further scrutiny include:

- The patient is a young age;
- The patient requests to pay cash when insurance coverage exists;
- One patient drops off or picks up multiple similar prescriptions for two or more patients;
- Similar or identical prescriptions originate from the same prescriber or practice for inordinately large quantities of medications typically diverted, such as OxyIR® or Xanax®;
- Groups of patients drop off similar or identical prescriptions for commonly diverted medications, often written by a prescriber who practices in another city or county;

- The patient presents controlled prescriptions from multiple physicians (suspicious for "doctor shopping");
- The patient is unable to provide identification when requested;
- All prescriptions from a particular provider for the same patient are phoned in to the pharmacy, and the pharmacy has never processed a written or faxed prescription from the provider for this patient;
- The diagnosis given by the patient does not match the diagnosis given by the prescriber;
- The prescriber is unable or unwilling to give a diagnosis or provides the same diagnosis for all patients, such as back pain or degenerative disc disease;
- The prescriber is unavailable to speak directly with the pharmacist, will not return calls entirely, or takes an unusual amount of time to respond to the pharmacist;
- The prescriber has not committed his or her DEA registration number to memory;
- The prescription does not contain all federally mandated information; or
- The prescription does not comply with tamper-resistance industry standards or appears tampered with.

When Tampering or Questionable Origin Is Suspected or Identified

If prescription tampering or a prescription of questionable origin is suspected or identified, pharmacists should choose to exercise their corresponding duty by electing not to fill the prescription. Pharmacists may be held accountable if they fill "customer prescriptions that they knew or should have known were not for legitimate medical use."[20] Pharmacists should report their suspicions. Agencies that may be notified include:

- Local law enforcement;
- DEA:
- State Medicaid Fraud Control Unit:
- State licensing board if a health care professional is involved; or
- The U.S. Department of Health and Human Services, Office of Inspector General.

ATTN: Hotline

P.O. Box 23489 Washington, D.C. 20026 Phone: 1-800-HHS-TIPS (1-800-447-8477)

Fax: 1-800-223-8164

Email: HHSTips@oig.hhs.gov

Website: https://forms.oig.hhs.gov/hotlineoperations/

Pharmacists should call 911 immediately in the event that a pharmacist, intern, technician or other pharmacy staff member feels threatened by a patient.



Conclusion

To help prevent prescription drug trafficking and to decrease the risk of diversion, pharmacy personnel must use special care when dealing with prescriptions for controlled substances and the patients who present them. Knowing how to recognize prescription tampering and which written prescription attributes should warrant secondary verification will help pharmacists and providers in the fight against these types of prescription fraud. Pharmacy personnel must exercise a corresponding responsibility to ensure prescriptions comply with all policies, procedures, and State and Federal laws prior to dispensing controlled substances.

References

- 1 Valiquette, J. (2013, March 28). Nearly 50 Arrested in Prescription Drug Trafficking Bust. NBC 4 New York. Retrieved July 17, 2014, from http://www.nbcnewyork.com/news/local/Prescription-Drug-Trafficking-Bust-Arrest-New-York-New-Jersey-Pennsylvania-Narcotics-Oxycodone-200432271.html
- 2 Medicaid Tamper Resistant Prescription Law-Pharmacist Fact Sheet. (2008). Retrieved July 17, 2014, from http://www.cms.gov/ Medicare-Medicaid-Coordination/Fraud-Prevention/FraudAbuseforProfs/downloads/pharmacisfactsheet.pdf
- 3 Centers for Medicare & Medicaid Services. Medicare Learning Network. (2008, April 1). Required Use of Tamper-Resistant Prescription Pads for Outpatient Drugs Prescribed to Medicaid Recipients on or After April 1, 2008. Retrieved July 17, 2014, from http://www.cms.gov/Outreach-and-Education/Medicare-Learning-Network-MLN/MLNMattersArticles/downloads/SE0736.pdf
- 4 National Council for Prescription Drug Programs. (2008, February 1). Retrieved August 18, 2014, from http://www.ncpanet.org/pdf/leg/letter ncpdp-meddir020108.pdf
- 5 Centers for Medicare & Medicaid Services. Tamper Resistant Prescriptions. (n.d.). Retrieved July 17, 2014, from http://www.cms.gov/Regulations-and-Guidance/Legislation/DeficitReductionAct/downloads/Tamperupdate.pdf
- 6 Frequently Asked Questions Concerning the Tamper-Resistant Prescription Law (Section 7002(b) of the U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act of 2007). (n.d.). Retrieved July 17, 2014, from http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/FraudAbuseforProfs/downloads/trpupdatedfaqs.pdf
- 7 National Council for Prescription Drug Programs. (2008, February 1). [State Medicaid Director Letter]. Retrieved July 17, 2014, from http://www.ncpanet.org/pdf/leg/letter_ncpdp-meddir020108.pdf

- 8 National Council for Prescription Drug Programs. (2008, February 1). [State Medicaid Director Letter]. Retrieved July 17, 2014, from http://www.ncpanet.org/pdf/leg/letter_ncpdp-meddir020108.pdf
- 9 Frequently Asked Questions Concerning the Tamper-Resistant Prescription Law (Section 7002(b) of the U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act of 2007). (n.d.). Retrieved July 17, 2014, from http://www.cms.gov/Medicare-Medicaid-Coordination/Fraud-Prevention/FraudAbuseforProfs/downloads/trpupdatedfaqs.pdf
- 10 Office of the Attorney General of Florida Pam Bondi. (n.d.). Florida's Prescription Drug Diversion and Abuse Roadmap 2012-2015. Retrieved July 17, 2014, from http://myfloridalegal.com/pages.nsf/main/aa7aaf5caa22638d8525791b006a30c8
- 11 Van Sickler, M. (2013, September 24). Bondi Touts Pill Mill Crackdown as Drug Deaths Drop. The Miami Herald. Retrieved July 17, 2014, from http://miamiherald.typepad.com/nakedpolitics/2013/09/bondi-touts-pill-mill-crackdown-as-drug-deaths-drop.html
- 12 U.S. Drug Enforcement Administration. (2013, June 11). Walgreens Agrees to Pay a Record Settlement of \$80 Million for Civil Penalties Under the Controlled Substances Act. Retrieved July 17, 2014, from http://www.justice.gov/dea/divisions/mia/2013/mia/061113.shtml
- 13 U.S. Drug Enforcement Administration. (2013, June 11). Walgreens Agrees to Pay a Record Settlement of \$80 Million for Civil Penalties Under the Controlled Substances Act. Retrieved July 17, 2014, from http://www.justice.gov/dea/divisions/mia/2013/mia/061113.shtml
- 14 U.S. Department of Justice. Drug Enforcement Administration. Office of Diversion Control. Purpose of Issue of Prescription, 21 C.F.R. § 1306.04. Retrieved July 17, 2014, from http://www.deadiversion.usdoj.gov/21cfr/cfr/1306/1306 04.htm
- 15 U.S. Department of Justice. U.S. Drug Enforcement Administration. (2012, October 12). Holiday CVS, L.L.C., d/b/a CVS/ Pharmacy Nos. 219 and 5195; Decision and Order. Retrieved July 17, 2014, from http://www.gpo.gov/fdsys/pkg/FR-2012-10-12/pdf/2012-25047.pdf
- 16 U.S. Department of Justice. U.S. Drug Enforcement Administration. (2010, October 27). East Main Street Pharmacy; Affirmance of Suspension Order. Retrieved July 17, 2014, from http://www.gpo.gov/fdsys/pkg/FR-2010-10-27/pdf/2010-27096.pdf
- 17 Ventura County Sheriff's Office. (2013, August 21). Simi Valley–Narcotics Task Force Arrests Local Pharmacist for Illegal Drug Sales. Retrieved July 17, 2014, from http://nixle.com/alert/5051377/
- 18 U.S. Department of Justice. (2013, June 24). Curbing Prescription Drug Abuse in Medicare (p. 8). Committee on Homeland Security and Governmental Affairs. [Senate Hearing]. Retrieved July 17, 2014, from http://www.justice.gov/dea/pr/speeches-testimony/2013t/062413-rannazzisi-testimony.pdf
- 19 National Alliance for Model State Drug Laws and the National Safety Council. (2013, July). Prescription Drug Abuse, Addiction and Diversion: Overview of State Legislative and Policy Initiatives. Retrieved July 17, 2014, from http://www.namsdl.org/library/716FD187-1C23-D4F9-745DA7F3D2169BAB/
- 20 U.S. Drug Enforcement Administration. (2013, June 11). Walgreens Agrees to Pay a Record Settlement of \$80 Million for Civil Penalties Under the Controlled Substances Act. Retrieved July 17, 2014, from http://www.justice.gov/dea/divisions/mia/2013/mia 061113.shtml

Disclaimer

This booklet was current at the time it was published or uploaded onto the web. Medicaid and Medicare policies change frequently so links to the source documents have been provided within the document for your reference.

This booklet was prepared as a service to the public and is not intended to grant rights or impose obligations. This booklet may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. Use of this material is voluntary. Inclusion of a link does not constitute CMS endorsement of the material. We encourage readers to review the specific statutes, regulations, and other interpretive materials for a full and accurate statement of their contents.

November 2014

